Profile: Verastem Inc (VSTM.OQ)
23 Sep 2016
Verastem, Inc., incorporated on August 4, 2010, is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company's advanced product candidates are VS 6063, VS 4718 and VS 5584. The Company's programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. FAK is a non-receptor tyrosine kinase encoded by the PTK-2 gene that is involved in cellular adhesion and, in cancer, metastatic capability. The Company is engaged in running clinical trials in cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.
The Company's VS-6063 (defactinib) is an orally available small molecule compound designed to inhibit FAK signaling. The Company is evaluating VS 6063 as a potential therapy for pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC) and other solid tumors. The Company is evaluating VS-6063 in a Phase I study in combination with Merck & Co.'s PD-1 inhibitor pembrolizumab and gemcitabine in patients with advanced pancreatic cancer, a Phase I/Ib trial in combination with weekly paclitaxel for patients with ovarian cancer, a Phase II study in patients with non-small cell lung cancer, a Phase II trial preceding surgery in mesothelioma, a combination trial of VS-6063 and VS-5584 in patients with relapsed mesothelioma, and a Phase I/Ib clinical collaboration with Pfizer Inc. and Merck KGaA to evaluate VS-6063 in combination with avelumab, an anti-PD-L1 antibody, in patients with ovarian cancer.
The Company's VS-4718 is an orally available small molecule compound designed to inhibit FAK signaling. The Company is evaluating VS‑4718 as a therapy for multiple solid tumors. The Company is conducting a Phase I, single-agent, dose escalation trial of VS-4718 in patients with advanced cancers and a Phase I, dose-escalation clinical trial evaluating 28-day cycles of VS 4718 in combination with gemcitabine (a chemotherapy) and nab-paclitaxel (Abraxane; a chemotherapy) in patients with advanced solid tumors.
The Company's VS-5584 is an orally available small molecule that inhibits both mTORC1/2 and PI3K signaling. The Company is engaged in conducting a Phase I, dose escalation clinical trial of its dual mTORC1/2 and PI3K inhibitor, VS-5584, in patients with advanced non-hematologic malignancies or lymphoma.
The Company competes with Astellas Pharma Inc., Celgene, Inc., Sanofi-Aventis U.S. LLC, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Pfizer Inc., OncoMed Pharmaceuticals, Inc., Dainippon Sumitomo Corp and Stemline Therapeutics, Inc.
117 Kendrick St Ste 500
NEEDHAM MA 02494-2730